Publication status: results come from company topline announcements, presentations, and filings and from a report of the Voyage topline results; one author states that adoption will depend on full peer-reviewed reporting of the Voyage and Panorama topline results.
Functional unblinding: Voyage used a two-arm design of DT120 100 µg versus placebo without the 50 µg low-dose comparator used in Panorama. Study drug-related TEAEs occurred in 95% of participants receiving DT120 and 48% receiving placebo, and illusion occurred on the dosing day in 75% and 10%. Baseline expectancy and perceived treatment were recorded; the cited disclosures report no results of these assessments. Central HAM-A raters were blinded to treatment assignment and visit number. Past psychedelic use was reported by 21% of participants.
Duration and dosing: the controlled comparison covers 12 weeks after a single dose. Part B is open label, and its results come from an interim analysis as of July 15, 2026, with 37 participants who received DT120 in Part A contributing HAM-A data at Week 28.
Comparator: placebo was the only comparator; no active GAD treatment was included. The placebo group improved by 6.2 points on HAM-A at Week 12.
Generalizability: participants were 18 to 74 years of age at approximately 35 sites in the United States, and people taking medications with anxiolytic or antidepressant effects that could not be discontinued, people with a personal or first-degree family history of psychotic or bipolar disorder, people with current alcohol or substance use disorder, and people in systematic psychotherapy within 4 weeks before screening were excluded.
Outcomes not reported in the cited disclosures: registered patient-reported, functioning, quality of life (PGI-S, WPAI-SHP, EQ-5D-5L), and sexual functioning (CSFQ-14) endpoints. The sponsor stated that Part B safety data are expected to be shared in a future presentation.
Discrepancies between sources: the share of participants clearing the end-of-session checklist by hour 8 is 92% in the topline announcement and 90% in the poster, and adverse events of special interest with DT120 are 100 (94%) in the topline presentation and 100 (93) in the poster.